{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=52",
    "query": {
      "intervention": "Peripheral Blood",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 20701,
    "total_pages": 2071,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T13:10:40.096Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01534247",
      "title": "A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CAZ-AVI",
          "type": "DRUG"
        },
        {
          "name": "metronidazole",
          "type": "DRUG"
        },
        {
          "name": "CAZ-AVI + metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-02",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2017-09-05",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01534247"
    },
    {
      "nct_id": "NCT04220658",
      "title": "Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epigenetics"
      ],
      "interventions": [
        {
          "name": "Biomarker study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Elysium Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 170,
      "start_date": "2019-12-19",
      "completion_date": "2023-12-03",
      "has_results": false,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04220658"
    },
    {
      "nct_id": "NCT07094685",
      "title": "Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Resectable Head and Neck Squamous Cell Carcinoma",
        "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ivonescimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2025-11-18",
      "completion_date": "2030-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07094685"
    },
    {
      "nct_id": "NCT03709043",
      "title": "Addressing Heavy Alcohol Use Consumption With Kudzu",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder",
        "Sexually Transmitted Diseases"
      ],
      "interventions": [
        {
          "name": "Standardized kudzu",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Sexually transmitted infection testing:",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Medical Management (MM) counseling for alcohol use:",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Urinalysis for novel alcohol biochemical markers for recent alcohol use:",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Dried Blood Spot (DBS) Testing for PEth:",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Behavioral survey measurements:",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Ecological Momentary Assessment procedure:",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "Glenn-Milo Santos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2019-07-11",
      "completion_date": "2024-06-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709043"
    },
    {
      "nct_id": "NCT00468208",
      "title": "Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Wegener's Granulomatosis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-02",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468208"
    },
    {
      "nct_id": "NCT04108858",
      "title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "HER2-Positive Breast Carcinoma",
        "Metastatic Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-05-20",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04108858"
    },
    {
      "nct_id": "NCT07752355",
      "title": "Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Young Onset Parkinson Disease",
        "Parkinson Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-02-28",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07752355"
    },
    {
      "nct_id": "NCT05807126",
      "title": "Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Castration-Resistant Prostate Carcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Magrolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-03-05",
      "completion_date": "2026-12-06",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 5,
      "location_summary": "Costa Mesa, California • Orange, California • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05807126"
    },
    {
      "nct_id": "NCT03110978",
      "title": "Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Atypical Carcinoid Tumor",
        "Lung Neuroendocrine Neoplasm",
        "Lung Non-Small Cell Squamous Carcinoma",
        "Minimally Invasive Lung Adenocarcinoma",
        "Neuroendocrine Carcinoma",
        "Recurrent Lung Adenocarcinoma",
        "Recurrent Lung Large Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage I Lung Cancer AJCC v8",
        "Stage IA1 Lung Cancer AJCC v8",
        "Stage IA2 Lung Cancer AJCC v8",
        "Stage IA3 Lung Cancer AJCC v8",
        "Stage IB Lung Cancer AJCC v8",
        "Stage IIA Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2017-06-26",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 3,
      "location_summary": "Conroe, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110978"
    },
    {
      "nct_id": "NCT00006108",
      "title": "Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-08",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2012-02-07",
      "last_synced_at": "2026-11-17T13:10:40.096Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006108"
    }
  ]
}